Enanta Pharmaceuticals, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ENTA Nasdaq 2836 www.enanta.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting - Feb 10th, 2026 5:00 am
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates - Feb 9th, 2026 3:05 pm
Enanta Pharmaceuticals: Fiscal Q1 Earnings Snapshot - Feb 9th, 2026 2:06 pm
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025 - Feb 9th, 2026 2:01 pm
JPM26: Enanta outlines strategy to lead in RSV therapeutics - Jan 15th, 2026 3:39 pm
Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook - Jan 8th, 2026 5:00 am
Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - Jan 5th, 2026 5:00 am
Enanta Pharmaceuticals Insider Ups Holding During Year - Jan 1st, 2026 6:03 am
Agios Pharmaceuticals (AGIO) Surges 18.6%: Is This an Indication of Further Gains? - Dec 26th, 2025 6:42 am
Enanta Pharmaceuticals (ENTA) Surges 5.9%: Is This an Indication of Further Gains? - Dec 22nd, 2025 7:17 am
Wall Street Analysts Believe Enanta Pharmaceuticals (ENTA) Could Rally 44.85%: Here's is How to Trade - Nov 21st, 2025 7:55 am
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025 - Nov 17th, 2025 2:01 pm
Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences - Nov 4th, 2025 5:00 am
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has caught the attention of institutional investors who hold a sizeable 44% stake - Nov 4th, 2025 4:40 am
Enanta Pharmaceuticals Presents New Data for Zelicapavir, its N-Protein Inhibitor, and EDP-323, its L-Protein Inhibitor, Both in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025 - Oct 20th, 2025 5:00 am
Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025 - Oct 7th, 2025 5:00 am
Enanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - Oct 2nd, 2025 2:01 pm
Traders Weigh US Government Shutdown, Fueling Premarket Losses for US Equity Futures - Oct 1st, 2025 7:10 am
FDA official’s comments spark Aurinia sell-off; Halozyme buys a biotech - Oct 1st, 2025 4:00 am
Enanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock - Sep 30th, 2025 7:00 pm